Kumar V - Search Results

1

Editorial: Recent Trends in Anticancer Drug Development: Challenges and Opportunities.

Skvortsova II, Kumar V. Skvortsova II, et al. Among authors: kumar v. Curr Med Chem. 2017 Jan 11;24(42):4727-4728. doi: 10.2174/092986732442180111141255. Curr Med Chem. 2017. PMID: 29378506 No abstract available.

2

Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review.

Kaur R, Dwivedi AR, Kumar B, Kumar V. Kaur R, et al. Among authors: kumar v, kumar b. Anticancer Agents Med Chem. 2016;16(4):465-89. doi: 10.2174/1871520615666150819121106. Anticancer Agents Med Chem. 2016. PMID: 26286663 Review.

3

A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.

Kumar B, Gupta VP, Kumar V. Kumar B, et al. Among authors: kumar v. Curr Drug Targets. 2017;18(1):87-97. doi: 10.2174/1389450117666151209123402. Curr Drug Targets. 2017. PMID: 26648064 Review.

4

Promising Targets in Anti-cancer Drug Development: Recent Updates.

Kumar B, Singh S, Skvortsova I, Kumar V. Kumar B, et al. Among authors: kumar v. Curr Med Chem. 2017;24(42):4729-4752. doi: 10.2174/0929867324666170331123648. Curr Med Chem. 2017. PMID: 28393696 Review.

5

Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer.

Singla H, Munshi A, Banipal RPS, Kumar V. Singla H, et al. Among authors: kumar v. Curr Cancer Drug Targets. 2018;18(4):306-327. doi: 10.2174/1568009617666170623122213. Curr Cancer Drug Targets. 2018. PMID: 28669349 Review.

6

Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.

Singla H, Ludhiadch A, Kaur RP, Chander H, Kumar V, Munshi A. Singla H, et al. Among authors: kumar v. Eur J Med Chem. 2017 Dec 15;142:316-327. doi: 10.1016/j.ejmech.2017.07.075. Epub 2017 Aug 1. Eur J Med Chem. 2017. PMID: 28800870 Review.

7

Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies.

Kumar B, Sharma P, Gupta VP, Khullar M, Singh S, Dogra N, Kumar V. Kumar B, et al. Among authors: kumar v. Bioorg Chem. 2018 Aug;78:130-140. doi: 10.1016/j.bioorg.2018.02.027. Epub 2018 Feb 28. Bioorg Chem. 2018. PMID: 29554587

8

Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.

Kumar B, Kumar V, Prashar V, Saini S, Dwivedi AR, Bajaj B, Mehta D, Parkash J, Kumar V. Kumar B, et al. Among authors: kumar v. Eur J Med Chem. 2019 Sep 1;177:221-234. doi: 10.1016/j.ejmech.2019.05.039. Epub 2019 May 16. Eur J Med Chem. 2019. PMID: 31151057

9

Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer.

Dwivedi AR, Thakur A, Kumar V, Skvortsova I, Kumar V. Dwivedi AR, et al. Among authors: kumar v. Curr Drug Targets. 2020;21(3):258-278. doi: 10.2174/1389450120666190821160730. Curr Drug Targets. 2020. PMID: 31433755 Review.

10

Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates.

Mal S, Dwivedi AR, Kumar V, Kumar N, Kumar B, Kumar V. Mal S, et al. Among authors: kumar v, kumar b, kumar n. Curr Med Chem. 2021;28(16):3193-3215. doi: 10.2174/0929867327666200716113136. Curr Med Chem. 2021. PMID: 32674727 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,180 results

Search Page

Filters